<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 S43 IS: Ethical Stem Cell Research Tax Credit Act of 2015</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2015-01-07</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>114th CONGRESS</congress><session>1st Session</session><legis-num>S. 43</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20150107">January 7, 2015</action-date><action-desc><sponsor name-id="S299">Mr. Vitter</sponsor> introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSFI00">Committee on Finance</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To amend the Internal Revenue Code of 1986 to provide a Federal income tax credit for certain stem
			 cell research expenditures.</official-title></form><legis-body><section id="S1" section-type="section-one"><enum>1.</enum><header>Short
 title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Ethical Stem Cell Research Tax Credit Act of 2015</short-title></quote>.</text></section><section id="idFE87EEFF70A34E108F2A98409D680BB1"><enum>2.</enum><header>Credit for
			 ethical stem cell research</header><subsection id="id274280557C9849DAB436B095B036ECDF"><enum>(a)</enum><header>In
 general</header><text>Subpart D of part IV of subchapter A of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/26/1">chapter 1</external-xref> of the Internal Revenue Code of 1986 is amended by adding at the end the following new section:</text><quoted-block display-inline="no-display-inline" id="id8BC6D2ED98634406BDD79FEDCAC160FA" style="OLC"><section id="ID719d1b938f8d4a999b0ea9350d35088f"><enum>45S.</enum><header>Ethical stem
				cell research</header><subsection id="ID0126c3df4c9a4148806e1e8d9b0391a0"><enum>(a)</enum><header>Allowance of
 credit</header><text>For purposes of section 38, in the case of an eligible taxpayer, the ethical stem cell research credit determined under this section for the taxable year shall be an amount equal to 30 percent of the qualified stem cell research expenses paid or incurred by the taxpayer during the taxable year.</text></subsection><subsection id="id994CD6936B514444B465D3C1C35B8FFE"><enum>(b)</enum><header>Eligible
 taxpayer</header><text>For purposes of this section, the term <term>eligible taxpayer</term> means any taxpayer that elects the application of this section for the taxable year.</text></subsection><subsection id="ID8e2c82f881ea4e979e3e823999680bb4"><enum>(c)</enum><header>Qualified stem
 cell research expenses</header><text>For purposes of this section—</text><paragraph id="ID1d3a6193df1549df989efa0e0f82bbf5"><enum>(1)</enum><header>In general</header><text>The term <term>qualified stem cell research expenses</term> means expenses which are paid or incurred by the eligible taxpayer during the taxable year in carrying on basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of or treatments for diseases and other adverse health conditions, no part of which may involve—</text><subparagraph id="id164511D3D9B54980BE8958A8E2217201"><enum>(A)</enum><text>the creation of a human embryo for research purposes,</text></subparagraph><subparagraph id="id44E5A0F825AB43BE9E5D652F68C3FA08"><enum>(B)</enum><text>the destruction of or discarding of, or risk of injury to, a human embryo, or</text></subparagraph><subparagraph id="id4C74C6469CB14AEA8BB4736E8442E82F"><enum>(C)</enum><text>the use of any stem cell, the derivation or provision of which would be inconsistent with subparagraph (A) or (B).</text></subparagraph></paragraph><paragraph id="IDfb14a75bdcb44dd48d43f31f02ebabe0"><enum>(2)</enum><header>Human
 embryo</header><text>The term <term>human embryo</term> means any organism not protected as a human subject under part 46 of title 45, Code of Federal Regulations (as in effect on the date of the enactment of this section) that is derived by fertilization, parthenogenesis, cloning, or any other means from one or more human gametes or human diploid cells.</text></paragraph><paragraph id="IDbfe5a93f62144d5d84793fa80af02854"><enum>(3)</enum><header>Risk of
 injury</header><text>The term <term>risk of injury</term> means subjecting a human embryo to risk of injury or death greater than that allowed for research on a fetus in utero under section 498(b) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/289g">42 U.S.C. 289g(b)</external-xref>) (as in effect on the date of the enactment of this section) and section 46.204(b) of title 45, Code of Federal Regulations (as so in effect).</text></paragraph></subsection><subsection id="ID0931027ab9bc4371a67e23fa7878cdd4"><enum>(d)</enum><header>Treatment of
				qualified stem cell research expenses</header><paragraph id="id0F398E5C579A4C1BA9F6C5B1732806C0"><enum>(1)</enum><header>In
 general</header><text>Except as provided in paragraph (2), any qualified stem cell research expenses for a taxable year to which an election under this section applies shall not be taken into account for purposes of determining the credit allowable under section 41 for such taxable year.</text></paragraph><paragraph id="id5457B6C4955B4783B33B09625F96577D"><enum>(2)</enum><header>Treated as base
 period research expenses</header><text>Any qualified stem cell research expenses for any taxable year which are qualified research expenses (within the meaning of section 41(b)) shall be taken into account in determining base period research expenses for purposes of applying section 41 to subsequent taxable years.</text></paragraph></subsection><subsection id="id3BEF191A687C4E79964670A57F12944B"><enum>(e)</enum><header>Special
 rules</header><paragraph id="idA6A996245EB74C4C9956A4C88EFDFE67"><enum>(1)</enum><header>Limitation</header><text>No credit shall be allowed under this section with respect to any stem cell research conducted by a corporation to which an election under section 936 applies.</text></paragraph><paragraph id="id8C4AB01AA668401F9059EDD4E60C5448"><enum>(2)</enum><header>Aggregation of
 expenditures and allocations of credit</header><text>Rules similar to the rules of paragraphs (1) and (2) of section 41(f) and section 41(g) shall apply for purposes of this section.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="idA323398CDA5A43018644404A01C29FA5"><enum>(b)</enum><header>Credit allowed
 as part of general business credit</header><text><external-xref legal-doc="usc" parsable-cite="usc/26/38">Section 38(b)</external-xref> of the Internal Revenue Code of 1986 is amended by striking <quote>plus</quote> at the end of paragraph (35), by striking the period at the end of paragraph (36) and inserting <quote>, plus</quote>, and by adding at the end the following new paragraph:</text><quoted-block display-inline="no-display-inline" id="idB20646D77DC34C04A7D7AB4F7D0F44BE" style="OLC"><paragraph id="idD3B845F19366478AA3977887B97EB19D"><enum>(37)</enum><text>the ethical stem cell research credit determined under section 45S(a).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="idD4ECBB5A3F8B489ABB43FB6538AAE6C3"><enum>(c)</enum><header>Denial of
			 double benefit</header><paragraph id="idC41CDB4C87D640E38A7823BBF26DD1FB"><enum>(1)</enum><header>Technical
 amendment</header><text>The second subsection (g) of <external-xref legal-doc="usc" parsable-cite="usc/26/280C">section 280C</external-xref> of the Internal Revenue Code of 1986, as added by section 1401(b) of the Patient Protection and Affordable Care Act, is redesignated as subsection (i).</text></paragraph><paragraph id="idD0B89CE8BA8F40EC8B5E7281B58844C5"><enum>(2)</enum><header>In
 general</header><text><external-xref legal-doc="usc" parsable-cite="usc/26/280C">Section 280C</external-xref> of the Internal Revenue Code of 1986, as amended by paragraph (1), is further amended by adding at the end the following new subsection:</text><quoted-block display-inline="no-display-inline" id="id31CEE631237B4786840F3C9BEBFE7C01" style="OLC"><subsection id="id4A5EDF1825754027B6687ACF7D730E4F"><enum>(j)</enum><header>Ethical stem
				cell research credit</header><paragraph id="ID0a9dda9d1a8b4f5a8aa20a28f5107e03"><enum>(1)</enum><header>In
 general</header><text>No deduction shall be allowed for that portion of the qualified stem cell research expenses (as defined in section 45S(c)(1)) otherwise allowable as a deduction for the taxable year which is equal to the amount of the credit determined for such taxable year under section 45S(a).</text></paragraph><paragraph id="IDad93f5f579f54bf7ae16abf39394d863"><enum>(2)</enum><header>Similar rule
				where taxpayer capitalizes rather than deducts
 expenses</header><text>If—</text><subparagraph id="ID5ebe7a9753a74a7d8ebdd1c341da7b60"><enum>(A)</enum><text>the amount of the credit determined for the taxable year under section 45S(a), exceeds</text></subparagraph><subparagraph id="IDc8744330994043df9d392a534f3699d9"><enum>(B)</enum><text>the amount allowable as a deduction for such taxable year for qualified stem cell research expenses (determined without regard to paragraph (1)),</text></subparagraph><continuation-text continuation-text-level="paragraph">the amount
				chargeable to capital account for the taxable year for such
			 expenses shall be
				reduced by the amount of such excess.</continuation-text></paragraph><paragraph id="ID98a8db84b16a410db4a25eae512e0228"><enum>(3)</enum><header>Controlled
 groups</header><text>Paragraph (3) of subsection (b) shall apply for purposes of this subsection.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="id7CB8D6C7B0744708BB0F9A45C29B9D33"><enum>(d)</enum><header>Clerical
 amendment</header><text>The table of sections for subpart D of part IV of subchapter A of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/26/1">chapter 1</external-xref> of the Internal Revenue Code of 1986 is amended by adding at the end the following new item:</text><quoted-block display-inline="no-display-inline" id="id5F071610B7F740E9B7838ACAD7E0C233" style="OLC"><toc regeneration="no-regeneration"><toc-entry level="section">Sec. 45S. Ethical stem cell
				research.</toc-entry></toc><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection commented="no" display-inline="no-display-inline" id="idDE44CB7A478F4792B1CCD82F64F0BCFC"><enum>(e)</enum><header>Effective
 Date</header><text>The amendments made by this section shall apply to amounts paid or incurred after the date of the enactment of this Act.</text></subsection></section></legis-body></bill>


